The Effect of Aliskiren and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients

• Status: Unknown status
• Trial end date: 2011-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a prospective, randomized, placebo controlled, multi-center clinical trial to determine whether aliskiren or aliskiren plus losartan or enalapril plus losartan effects on peritoneal membrane transportation.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chulalongkorn University
• Treatments: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Enalapril; Enalaprilat; Enzyme Inhibitors; Losartan

Criteria

Inclusion Criteria:

1. All patients received continuous ambulatory peritoneal dialysis less than one and a half years

2. Subjects of either sex, more than 20 years old

3. Hypertension

4. Provision of written informed consent by subject or guardian

Exclusion Criteria:

1. No history of taking an angiotensin converting enzyme inhibitor or angiotensin-receptor blockers or aldosterone antagonist for at least 2 month

2. Serum potassium more than 5.5 mEq/L

3. History of renal artery stenosis

4. Peritonitis or volume overload within the preceding 1 month

5. Myocardial infarction within the preceding 6 months or clinically significant valvular disease or any active cardiovascular disease

6. History of malignant hypertension or hypertensive encephalopathy or cerebrovascular accident within the preceding 6 months

7. Any condition that may have precluded a patient from remaining in the study, such as alcohol or drug abuse, chronic liver disease, malignant disease, or psychiatric disorder

8. History of allergy or intolerance to an angiotensin converting enzyme inhibitors or angiotensin receptor blockers

9. Hypotension defined as systolic blood pressure less than 90 mmHg